BDH2

Across TCGA pan-cancer cohorts, BDH2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BDH2 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BDH2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated BDH2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

CCRCC, COAD, and PDAC are the cancer types where BDH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	1.000	0.839	.009	20	view →
COAD	DFS	Tertile	II,III,IV	1.000	0.907	.041	12	view →
PDAC	DFS	Quartile	All	0.531	0.311	.009	10	view →
LUAD	DFS	Quartile	II,III,IV	0.627	0.972	.025	2	view →
HNSC	DFS	Median	III,IV	0.992	0.913	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BDH2–CCRCC (OS)

Open the CCRCC breakdown →